Mineralys Therapeutics (MLYS) Capital Expenditures (2024 - 2025)
Mineralys Therapeutics' (MLYS) quarterly Capital Expenditures came in at $15000.0 in Q4 2025, down 59.46% quarter-over-quarter from $37000.0 in Q3 2024.
Mineralys Therapeutics (MLYS) Capital Expenditures (2024 - 2025) Analysis & Trends
Mineralys Therapeutics has disclosed Capital Expenditures across 2 years of filings, most recently posting $15000.0 for Q4 2025.
- Capital Expenditures for Q4 2025 came in at $15000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $15000.0 (down 84.38% YoY), and the FY2025 annual result was $15000.0, down 84.38% from the prior year.
- Capital Expenditures came in at $15000.0 for Q4 2025 at Mineralys Therapeutics, down from $37000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $59000.0 in Q1 2024 to a low of $15000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -63,220.27 |
| 10 | Mineralys Therapeutics | 1.95 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Mar 31, 2024 | 59,000.00 |